Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
Urology Case Reports
Genomics; Neuroendocrine; Prostate
© 2016 Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.
Kim, H., Alshalalfa, M., Hoffman-Censits, J., Lallas, C., Davicioni, E., Lin, J., Birbe, R., Erho, N., Lehrer, J., Ashab, H., Takhar, M., Olson, A., Lam, L., Kelly, W., Knudsen, K., Thangavel, C., Seiler, R., Feng, F., Schaeffer, E., Trabulsi, E., Gomella, L., Hurwitz, M., Dicker, A., & Den, R. (2016). Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 9 (). http://dx.doi.org/10.1016/j.eucr.2016.08.010